Contact urticaria is localized color changes and swelling on the skin that appear immediately after coming into contact with a specific substance. Contact urticaria can result from a variety of ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

but can now point to a win for rilzabrutinib in chronic spontaneous urticaria (CSU). In a phase 2 trial, rilzabrutinib has been shown to rapidly reduce itch severity and significantly improve ...

Story April 14 - Third Harmonic Bio: The California biotech has abandoned plans to take its chronic spontaneous urticaria drug into phase 2, instead preparing to sell the asset while liquidating ...

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development. La Merie Publishing offers an e-mail notification service about the release of new products ...